Boston Scientific Corp

BSX

Equity

ISIN US1011371077 / Valor 913577

New York Stock Exchange, Inc (2024-11-21)

USD 91.50+1.47%

Boston Scientific Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Boston Scientific Corp is a global leader in the development, manufacturing, and marketing of medical devices designed to address a wide array of medical conditions through less-invasive technologies. The company's core business areas include Cardiac Rhythm Management, Electrophysiology, Endoscopy, Interventional Cardiology Therapies, Neuromodulation, Peripheral Interventions, Urology, and the WATCHMAN device for cardiac care. Boston Scientific is committed to enhancing patient outcomes, reducing healthcare costs, and increasing efficiencies within the medical field.

Summarized from source with an LLMView SourceSector: Healthcare

Net Sales Growth

Boston Scientific Corp reported net sales of $4.120 billion for the second quarter of 2024, marking a 14.5% increase on a reported basis compared to the same period last year. On an operational basis, net sales grew by 16.1%, and on an organic basis, they increased by 14.7%.

Net Income and EPS

For the second quarter of 2024, Boston Scientific Corp reported a GAAP net income attributable to common stockholders of $324 million, or $0.22 per share. This is an improvement from the $261 million, or $0.18 per share, reported in the same quarter of the previous year. The company also achieved an adjusted EPS of $0.62, up from $0.53 a year ago.

Segment Performance

Boston Scientific Corp's MedSurg segment saw a net sales growth of 9.0% on a reported basis, 10.1% on an operational basis, and 7.6% on an organic basis. The Cardiovascular segment experienced a more robust growth, with net sales increasing by 17.8% on a reported basis, 19.7% on an operational basis, and 19.0% on an organic basis.

Regional Sales Growth

In the second quarter of 2024, Boston Scientific Corp achieved notable net sales growth across various regions. In the United States, sales grew by 16.9% on both reported and operational bases. In Europe, the Middle East, and Africa (EMEA), sales increased by 13.7% on a reported basis and 16.1% on an operational basis. The Asia-Pacific region saw a 7.0% increase on a reported basis and 13.2% on an operational basis, while Latin America and Canada (LACA) experienced a 15.3% increase on a reported basis and 15.7% on an operational basis.

Future Outlook

Boston Scientific Corp remains optimistic about its future, driven by its commitment to innovation and strategic investments. CEO Mike Mahoney highlighted the company's exceptional performance in the second quarter of 2024 and expressed gratitude for the dedication and winning spirit of the global team. The company continues to focus on category leadership and strong clinical evidence to support its growth plans.

Summarized from source with an LLMView Source

Key figures

65.4%1Y

123%3Y

116%5Y

Performance

16.9%1Y

22.3%3Y

28.2%5Y

Volatility